(11.3% vs 0%; mean concentration [range], 0.979 [0.70-1.25] mmol/L vs 0.858 [0.60-1.05] mmol/L). Additionally,
abnormal urine pH developed in a greater proportion of patients in the P/MC treatment arm compared with patients in the 2L PEG-3350 and bisacodyl tablets treatment arm (23.4% vs 7.6%; mean pH [range], 6.74 [5.5-8.5] vs
6.24 [5.0-8.0]). At the 48-hour follow-up visit, shifts in these parameters were resolved or resolving. The shifts in magnesium values and urine pH were generally comparable between the treatment arms at the 7-day and 28-day followup visits and had returned to normal thresholds by the end of the study.